It is with deep sadness that we announce the passing of Joseph Wilson, who passed away peacefully on December 29th, 2024 at the age of 67. Joe was born February 7, 1957, he grew up in Zanesville ...

In the last few years, Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry. With multiple programs now nearing proof-of ...

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief strategy officer said. Mitsubishi Tanabe Pharma is being sold to Bain Capital ...

Astellas has shored up the competitive profile of Izervay as a treatment for eye disorder geographic atrophy (GA), getting FDA approval for an extended treatment duration. The US regulator turned ...

The Cultural Institute of Radical Contemporary Arts (CIRCA) today unveils the 30 shortlisted artists for the CIRCA PRIZE 2023 — an initiative that invests in the future of art and culture by awarding ...

Russell Wilson had a short and not-so-great stint with the Denver Broncos in the 2022 and 2023 seasons. He spent last season in Pittsburgh, where he had some ups and downs, but overall ...

According to IQVIA figures, US sales of Lexiscan were approximately $650 million for the 12 months that ended 31 March 2022, making it one of Astellas top products. It was first launched in the US ...

Astellas also revealed today that it is terminating the development of ASP2390, a DNA vaccine for house dust mite-induced allergic rhinitis, and GITR agonist antibody ASP1951 for cancer – both ...

Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Japanese pharma said its wholly-owned subsidiary Universal ...

Astellas has suffered another major setback with geographic atrophy (GA) treatment Izervay, this time in the US. The company has received a complete response letter (CRL) from the FDA for a ...

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy (GA), based on feedback from the EU regulator. It is a major ...

Astellas acquired fezolinetant as part of its 2017 takeover of Ogeda for €500 million (at the time equivalent to around $550 million) upfront plus €300 million in potential milestones. Image ...